Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Fineline Cube Aug 6, 2026
Company Drug

Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment

Fineline Cube May 12, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...

Company Deals

Eli Lilly and Purdue Expand Partnership With $250 Million Investment

Fineline Cube May 12, 2025

US-based Eli Lilly & Co. (NYSE: LLY) and Purdue University have expanded their long-term partnership...

Company Drug

CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study

Fineline Cube May 12, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...

Company Drug

CSPC Receives FDA Approval for SYH2046 in Heart Failure After Acute Myocardial Infarction

Fineline Cube May 12, 2025

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG

Fineline Cube May 12, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from Japan’s Pharmaceuticals and...

Company Deals Drug

Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development

Fineline Cube May 12, 2025

China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...

Company Drug

InnoCare Pharma’s Mesutoclax Granted Breakthrough Therapy Designation for R/R MCL

Fineline Cube May 12, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation...

Company

AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi

Fineline Cube May 12, 2025

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has commenced the construction of a new small...

Company Drug

IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma

Fineline Cube May 12, 2025

China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...

Company Drug

Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity

Fineline Cube May 12, 2025

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...

Company Drug

RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis

Fineline Cube May 12, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...

Company Drug

NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Deals

XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million

Fineline Cube May 12, 2025

Shenzhen-based XtalPi Holdings Limited (HKG: 2228) announced plans to acquire a 90% stake in Re...

Company Medical Device

Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters

Fineline Cube May 12, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Drug

Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval

Fineline Cube May 9, 2025

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...

Company Drug

J&J’s Tremfya Approved for Ulcerative Colitis in China

Fineline Cube May 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...

Policy / Regulatory

China’s CDE Reveals 93rd Batch of Reference Preparations for GQCE

Fineline Cube May 9, 2025

China’s Center for Drug Evaluation (CDE) has released the 93rd batch of reference preparations for...

Policy / Regulatory

NHC Issues Guidelines for Geriatric Medicine Departments Construction and Management

Fineline Cube May 9, 2025

The National Health Commission (NHC) this week released the “Guidelines for the Construction and Management...

Company

Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales

Fineline Cube May 9, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April...

Company

Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress

Fineline Cube May 9, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report...

Posts pagination

1 … 203 204 205 … 704

Recent updates

  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
  • RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal
  • Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance
  • Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint
  • China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects

Company

RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal

Company

Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance

Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.